$75 million in second quarter VYVGART® (efgartigimod alfa-fcab) global net product sales from U.S. and Japan commercial launch; approval in Europe on track for third quarter 2022 Biologics License Application
argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
July 21, 2022Breda, the Netherlands – argenx , a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will. | July 21, 2022